New post-cryptogenic stroke remote telemetry study demonstrates increased atrial fibrillation detection and USD 4 million in cost savings using initial Philips BioTel Heart MCOT monitoring
09 März 2022 - 10:00AM
New post-cryptogenic stroke remote telemetry study demonstrates
increased atrial fibrillation detection and USD 4 million in cost
savings using initial Philips BioTel Heart MCOT monitoring
March 9, 2022
- As an initial remote monitoring diagnostic approach, Philips
BioTel Heart MCOT detected 4.6 times more patients with atrial
fibrillation compared to implantable loop recorder alone
- Almost eight times lower costs were achieved with improved
detection rates and reduction of secondary stroke risk
- Remote cardiac monitoring via the MCOT patch reduced the total
cost per patient with detected atrial fibrillation by USD 198,909
compared to monitoring with ILR only
- Findings validate 30-day remote cardiac monitoring program as
cost-effective standard of care for cryptogenic stroke patients
compared to ILR alone
Amsterdam, the Netherlands – Royal Philips
(NYSE: PHG, AEX: PHIA), a global leader in health technology, has
announced new research evaluating mobile cardiac outpatient
telemetry (MCOT) as a first-line diagnostic ambulatory monitoring
solution with post-cryptogenic stroke patients. The study
determined that a 30-day continuous monitoring program using the
Philips BioTel Heart MCOT patch, followed by an implantable loop
recorder (ILR), improved atrial fibrillation (AF) detection rates
and helped to reduce secondary stroke risk due to new anticoagulant
use in subjects with the MCOT patch detected AF. The study also
demonstrated that use of initial MCOT monitoring achieved almost
eight times lower costs, reducing the total cost per patient with
detected atrial fibrillation (AF) by USD 198,909 [1], compared to
monitoring with ILR only. These results strengthen
recommendations for prolonged ECG monitoring for this patient
population.
Globally, about one in four people over the age of 25 will
suffer a stroke in their lifetime [2]. Nearly a third of Ischemic
strokes – the result of blood clots that block the flow of blood to
the brain – are classified as cryptogenic, meaning the cause is
unknown [3]. These situations require post-stroke diagnostic work
to determine the cause and prevent a second stroke from occurring.
AF is a common cause and can increase the risk of stroke by more
than five times [4], but it often goes undetected since it can be
asymptomatic and may occur infrequently.
The study evaluated a stroke population of 1,000 for one year to
assess the differences in costs and outcomes of two monitoring
options that are available to clinicians today to help improve
patient care and improve efficiencies within the healthcare system.
Findings revealed using an MCOT patch followed by ILR in half of
patients initially undiagnosed with AF leads to an overall
cost-of-care savings of more than USD 4 million. Philips BioTel
Heart MCOT detected 4.6 times more patients with AF than ILR alone.
And for those with detected AF, the cost per patient was
significantly lower when using the MCOT patch followed by ILR (USD
29,598) than those being monitored with ILR alone (USD
228,507).
“The diagnostic tools clinicians use to monitor this group of
patients play an important role in finding the cause of the stroke
and developing a personalized treatment plan,” said Andy Broadway,
General Manager of Ambulatory Monitoring and Diagnostics at
Philips. “This new research confirms that using Philips BioTel
Heart MCOT as the first line of evaluation is more cost-effective
and can provide the level of diagnostic confidence needed to help
detect and diagnose atrial fibrillation, and potentially prevent a
second stroke.”
Patients were monitored for 30 days and were included in one of
two monitoring arms in the model: The MCOT patch arm where Philips
BioTel Heart MCOT was used followed by ILR in undetected AF
patients for 30 days, or the ILR arm where ILR served as the only
monitoring tool.
Philips solutions across care pathwaysPhilips
offers a complete portfolio of clinically validated ambulatory
cardiac diagnostic and monitoring services as well as stroke care
solutions that provide industry-leading data analysis and
management to help make care delivery more comprehensive, accurate
and efficient.These solutions aim to connect information,
technologies and people across both the stroke and cardiac care
pathways, enabling care teams to work quickly and act decisively to
provide the best patient treatment. The new research results
illustrate the company’s strong commitment to further innovation in
this field.
For more information on Philips’ full portfolio of cardiology
solutions being showcased during the HIMSS22 Global Health
Conference & Exhibition, please visit www.philips.com/himss and
follow @PhilipsLiveFrom for #HIMSS22 updates throughout the
event.
[1] Difference in cost per patient with detected AF monitored
with ILR ($228,507) minus cost per patient with detected AF
patients using the MCOT patch ($29,598). Medic G, Kotsopoulos N,
Connolly MP, Lavelle J, Norlock V, Wadhwa M, Mohr BA, Derkac WM.
Mobile Cardiac Outpatient Telemetry Patch vs Implantable Loop
Recorder in Cryptogenic Stroke Patients in the US -
Cost-Minimization Model. Med Devices (Auckl). 2021 Dec
18;14:445-458. doi: 10.2147/MDER.S337142. PMID: 34955658; PMCID:
PMC8694406.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8694406/
[2] Feigin VL, Brainin M, Norrving B, Martins S, Sacco RL, Hacke
W, Fisher M, Pandian J, Lindsay P. World Stroke Organization (WSO):
Global Stroke Fact Sheet 2022. Int J Stroke. 2022 Jan;17(1):18-29.
doi: 10.1177/17474930211065917. PMID: 34986727.
https://pubmed.ncbi.nlm.nih.gov/34986727
[3] Finsterer J. Management of cryptogenic stroke. Acta Neurol
Belg. 2010 Jun;110(2):135-47. PMID: 20873443.
https://pubmed.ncbi.nlm.nih.gov/20873443
[4] Oladiran O, Nwosu I. Stroke risk stratification in atrial
fibrillation: a review of common risk factors. J Community Hosp
Intern Med Perspect. 2019;9(2):113-120. Published 2019 Apr 12.
doi:10.1080/20009666.2019.1593781
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6484493/
For further information, please contact:
Meredith AmorosoPhilips Global Press OfficeTel: +1
724-584-8991E-mail: meredith.amoroso@philips.com
About Royal PhilipsRoyal Philips (NYSE: PHG,
AEX: PHIA) is a leading health technology company focused on
improving people's health and well-being, and enabling better
outcomes across the health continuum – from healthy living and
prevention, to diagnosis, treatment and home care. Philips
leverages advanced technology and deep clinical and consumer
insights to deliver integrated solutions. Headquartered in the
Netherlands, the company is a leader in diagnostic imaging,
image-guided therapy, patient monitoring and health informatics, as
well as in consumer health and home care. Philips generated 2021
sales of EUR 17.2 billion and employs approximately 78,000
employees with sales and services in more than 100 countries. News
about Philips can be found at www.philips.com/newscenter.
- A care provider applies and explains Philips MCOT patch
Koninklijke Philips NV (BIT:1PHIA)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Koninklijke Philips NV (BIT:1PHIA)
Historical Stock Chart
Von Apr 2023 bis Apr 2024